

FORM PTO-1390 (Modified) (REV 10-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <div style="text-align: center; font-weight: bold;">BB1129</div>	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR) <div style="font-size: 1.5em; font-family: monospace;">09/831233</div>	
INTERNATIONAL APPLICATION NO. <div style="text-align: center; font-weight: bold;">PCT/US99/25950</div>		INTERNATIONAL FILING DATE <div style="text-align: center; font-weight: bold;">4 NOVEMBER 1999 (04.11.99)</div>		PRIORITY DATE CLAIMED <div style="text-align: center; font-weight: bold;">5 NOVEMBER 1998 (05.11.98)</div>	
TITLE OF INVENTION <div style="text-align: center; font-weight: bold;">PLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS</div>					
APPLICANT(S) FOR DO/EO/US <div style="text-align: center; font-weight: bold;">STEPHEN M. ALLEN ET AL.</div>					
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information</p> <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to being national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application was filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau. b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c) (2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c) (3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409) 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). <p>Items 13 to 18 below concern document(s) or information included :</p> <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. <input type="checkbox"/> A substitute specification. 17. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter. 18. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail. 19. <input checked="" type="checkbox"/> Other items or information: <div style="border: 1px solid black; padding: 10px; margin-top: 10px;"> <p>17. General Power of Attorney</p> <p>18. Express Mailing Label No.: EH235655477US</p> <p>19. Sequence Listing Diskette and Paper Copy - 14 pages Declaration in Accordance with 37 CFR 1.821</p> </div>					

APPLICATION NO. (IF KNOWN, SEE 37 CFR) 09/831233		INTERNATIONAL APPLICATION NO PCT/US99/25950		ATTORNEY'S DOCKET NUMBER BB1129	
--	--	---	--	---	--

20. The following fees are submitted

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)) :

☒ Search Report has been prepared by the EPO or JPO \$860.00

☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) \$690.00

☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00

☐ Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1000.00

☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (c)). ☐ 20 ☐ 30 **\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	18 - 20 =	0 x	\$18.00	\$0.00
Independent Claims	2 - 3 =	0 x	\$80.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00
TOTAL OF ABOVE CALCULATIONS =				\$860.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00
SUBTOTAL =				\$860.00
Processing Fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00
TOTAL NATIONAL FEE =				\$860.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00
TOTAL FEES ENCLOSED =				\$860.00

Amount to be :
refunded \$

Charged \$

☐ A check in the amount of _____ to cover the above fees enclosed.

☒ Please charge my Deposit Account No. **04-1928** in the amount of **\$860.00** to cover the above fees.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **04-1928** a duplicate copy of this sheet is enclosed.

NOTE : Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (CFR 1.37(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

LI, Kening
E. I. DU PONT DE NEMOURS AND COMPANY
Legal Patent Records Center
1007 Market Street
Wilmington, Delaware 19898
United States of America

SIGNATURE _____

NAME **LI, KENING**

REGISTRATION NUMBER **44,872**

DATE **04 MAY 2001**

09/831233

JC18 Rec'd PCT/PTO 04 MAY 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

STEPHEN M. ALLEN ET AL.

CASE NO.: BB1129 PCT

APPLICATION NO.: UNKNOWN

GROUP ART UNIT: UNKNOWN

FILED: CONCURRENTLY HERewith

EXAMINER: UNKNOWN

FOR: PLANT GLUTAMINE AMIDOTRANSFERASE
HOMOLOGS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the application as follows:

In the specification

At page 8, line 11, please replace "effect" with affect".

At page 10, line 19, please replace "effecting" with
"affecting".

At page 22, line 31, please replace "effect" with
"affect".

In the Claims:

Please cancel claims 1-23.

Please add the following new claims:

--24. An isolated polynucleotide that encodes a histidine biosynthetic enzyme polypeptide having a sequence identity of at least 85% based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12 and 14.

25. The polynucleotide of Claim 24 wherein the sequence identity is at least 90%.

26. The polynucleotide of Claim 24 wherein the sequence identity is at least 95%.

27. The polynucleotide of Claim 24 wherein the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12 and 14.
28. An isolated complement of the polynucleotide of Claim 24, wherein (a) the complement and the polynucleotide consist of the same number of nucleotides, and (b) the nucleotide sequences of the complement and the polynucleotide have 100% complementarity.
29. An isolated nucleic acid molecule that remains hybridized with the isolated polynucleotide of Claim 24 under a wash condition of 0.1X SSC, 0.1% SDS, and 65°C.
30. A cell or a virus comprising the polynucleotide of Claim 24.
31. The cell of Claim 30, wherein the cell is selected from the group consisting of a yeast cell, a bacterial cell, an insect cell, and a plant cell.
32. A transgenic plant comprising the polynucleotide of Claim 24.
33. A method for transforming a cell comprising introducing into a cell the polynucleotide of Claim 24.
34. A method for producing a transgenic plant comprising (a) transforming a plant cell with the polynucleotide of Claim 24, and (b) regenerating a plant from the transformed plant cell.
35. An isolated histidine biosynthetic enzyme polypeptide having a sequence identity of at least 95% based on the Clustal method compared to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12 and 14.
36. The isolated polypeptide of Claim 35 wherein the sequence identity is at least 90%.
37. The isolated polypeptide of Claim 35 wherein the sequence identity is at least 95%.
38. The polypeptide of Claim 35 wherein the polypeptide has a sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12 and 14.
39. A chimeric gene comprising the polynucleotide of Claim 24 operably linked to at least one suitable regulatory sequence.

Application No.: Unknown
Docket No.: BB1129 PCT

Page 3


40. The chimeric gene of Claim 39, wherein the chimeric gene is an expression vector.
41. A method for altering the level of a histidine biosynthetic polypeptide expression in a host cell, the method comprising:
- (a) Transforming a host cell with the chimeric gene of claim 39; and
 - (b) Growing the transformed cell in step (a) under conditions suitable for the expression of the chimeric gene. --

Remarks

Applicants respectfully submit that the amendment to the Specification only corrects obvious typographical errors. Furthermore, applicants submit that newly added claims more clearly and distinctly recite that which applicants consider to be their invention, and are adequately supported by the original disclosure. For example, the Clustal method of alignment is described at page 23, line 17 et seq.

No new matter is believed to be at issue. Entry of the amendments and early favorable consideration of the claims on the merits are hereby respectfully requested.

Respectfully submitted,



KENING LI
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 44,872
TELEPHONE: 302-992-3749
FACSIMILE: 302-892-1026

Dated:

05/04/2001

SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company
<120> Plant Glutamine Amidotransferase Homologs
<130> BB1129
<140>
<141>
<150> 60/107,275
<151> 1998-11-05
<160> 15
<170> Microsoft Office 97
<210> 1
<211> 1956
<212> DNA
<213> Impatiens balsamia

<400> 1
gcacgagaag gaactggcaa gtaccaagcc acagaatggg ttcagaattc gcgcccgcctt 60
ggctgggtgca ggcgggagatt ctgtgggtgac tttacttgat tacgggtgctg gaaatgttag 120
gagtggtgagg aacgccatcc gcacacttgg atttgatatc aaagatgtgc aaaagccaga 180
ggatattcta aatgctaagc gccttatctt tcctggcggtt ggggcctttg cacctgcaat 240
ggatgttctt attcgtaaa ggcctggctga agcactctgt acttacattc agaattgatcg 300
acctttcctg ggtatatgcc tgggattgca gctactcttt gagtcaagtg aagaaaatgg 360
tccaattcaa ggtcttggct tgattcctgg acgggttggg cgttttgaat catccaatgg 420
tttaagggtg ccacatattg gatggcatgc cttggatata aaggaagggt cagcaatttt 480
agatgatgtg gggaaatcaac atgtgtatct tggttcactca tatcgagcca atgccgagga 540
caacaaagag tggatttcat ctacatgcag ctatgggtgac gattttattg catccattca 600
gaagggaaat gttcatgcag tccaatttca tcccagagaag agtggagggt ttggactttc 660
catattgaga agatttttga atgctgattc ctttaacaac aaaagacaga agccaatgaa 720
tggaaaggct tctaaacttg caaagagagt aattgcttgc cttgatgtga gggcaaata 780
taatggggat cttgttgtaa ccaagggaga ccaatatgat gtgagagaac gtacagaaga 840
gaatgagggtc agaaaccttg gcaagcctgt tgaacttgct gggcagttat atttagacgg 900
tgctgatgag gtcagcttct taaacattac tggtttccgg gacttccctc taggcgatct 960
acccatgcta caggtcttgc aacgcgcac tgaacacggt tttgtgccat taactgtcgg 1020
gggtggcatc agggatttta ctgatgcaaa tgggaaggat tattctagtc tagaagtggc 1080
ttcagagtat ttcagatcgg gcgcccataa ggtttcgac ggaagtgatg cagtttacac 1140
tgctgaggaa tatattaaaa ccggagtga gacaggaaa agcagcatag agcagatata 1200
tacagtatat ggtaaccagg cagtgggtgt aagcattgat cctcgccgag tttacttgag 1260
aaaaccgat gaagtagaat ttaaagccat caaagtaagc catccaggtc caaacggtga 1320
ggaatatgcc tggatcagc gcaactgtta tgggtggacga gaagggagac ccacggagc 1380
ttatgaacta gctaaggctg ttgaggaact tggagctgga gaaatattat tgaactgcat 1440
tgattgtgat ggtcaaggaa aaggattcga tatagatctg atcaagctaa tatccgatgc 1500
tgtgaacatt cctgttatcg caagcagcgg tgcaggagtc gctgatcact tctccgaagt 1560
ctttaatgaa accaacgcat ctgctgcct tgcagctggc attttccatc gcaaagaggt 1620
tccaattaa gctgttaaag agcacttggt gaaggaaggg attgaagtta gattgtaagg 1680
cgagaatcac ttggaagaaa tttcatcttg aagttcaatt ttgttacaca agagatttcc 1740
ttctttcttg gctatgtga tatattttta tttatgtttt gctattgaat tattgttatt 1800
attatttttg catttgttat ttgaatagat ttgagttttt agaccttggg gtgtcctggt 1860
tatctctagg ccattgtttg tggattatat acaagtgtga aattaaata ataaatcgta 1920
tgaatttatg cttttaaaaa aaaaaaaaaa aaaaaa 1956

<210> 2
<211> 558

<212> PRT

<213> Impatiens balsamia

<400> 2

```

His Glu Lys Glu Leu Ala Ser Thr Lys Pro Gln Asn Gly Phe Arg Ile
 1          5          10          15

Arg Ala Ala Leu Ala Gly Ala Gly Gly Asp Ser Val Val Thr Leu Leu
 20          25          30

Asp Tyr Gly Ala Gly Asn Val Arg Ser Val Arg Asn Ala Ile Arg Thr
 35          40          45

Leu Gly Phe Asp Ile Lys Asp Val Gln Lys Pro Glu Asp Ile Leu Asn
 50          55          60

Ala Lys Arg Leu Ile Phe Pro Gly Val Gly Ala Phe Ala Pro Ala Met
 65          70          75          80

Asp Val Leu Ile Arg Lys Gly Leu Ala Glu Ala Leu Cys Thr Tyr Ile
 85          90          95

Gln Asn Asp Arg Pro Phe Leu Gly Ile Cys Leu Gly Leu Gln Leu Leu
100          105          110

Phe Glu Ser Ser Glu Glu Asn Gly Pro Ile Gln Gly Leu Gly Leu Ile
115          120          125

Pro Gly Arg Val Gly Arg Phe Glu Ser Ser Asn Gly Leu Arg Val Pro
130          135          140

His Ile Gly Trp His Ala Leu Asp Ile Lys Glu Gly Ser Ala Ile Leu
145          150          155          160

Asp Asp Val Gly Asn Gln His Val Tyr Phe Val His Ser Tyr Arg Ala
165          170          175

Asn Ala Glu Asp Asn Lys Glu Trp Ile Ser Ser Thr Cys Ser Tyr Gly
180          185          190

Asp Asp Phe Ile Ala Ser Ile Gln Lys Gly Asn Val His Ala Val Gln
195          200          205

Phe His Pro Glu Lys Ser Gly Gly Val Gly Leu Ser Ile Leu Arg Arg
210          215          220

Phe Leu Asn Ala Asp Ser Phe Asn Asn Lys Arg Gln Lys Pro Met Asn
225          230          235          240

Gly Lys Ala Ser Lys Leu Ala Lys Arg Val Ile Ala Cys Leu Asp Val
245          250          255

Arg Ala Asn Asp Asn Gly Asp Leu Val Val Thr Lys Gly Asp Gln Tyr
260          265          270

Asp Val Arg Glu Arg Thr Glu Glu Asn Glu Val Arg Asn Leu Gly Lys
275          280          285

Pro Val Glu Leu Ala Gly Gln Tyr Tyr Leu Asp Gly Ala Asp Glu Val
290          295          300

```


<220>
<221> unsure
<222> (518)

<220>
<221> unsure
<222> (577)

<220>
<221> unsure
<222> (582)

<400> 3
aagaaaaggc ccgctagggc gccgagacag cggaacgttc tctgagtttg agcacgatct 60
ccccggggccc cggcgccgcc gtacgtcccc ctccggcgtc gccagccgcc tccctggctcc 120
ggctccttca tcgcctgctc cagcgtgcct gcgtgacata agcgtcgatt gattggcgag 180
aaaggggacg aatgcagccg ccgttgacag cgcagggagc aatggctaac gtcgccgcta 240
tctcaccgt cccctgctcc gcgggcccgc gcccgaaagc gagcaaccag ccccgccgat 300
gcggtccgt ctccgtctcc gtctccgtcc gtgcgtcctc cggcgcaaac acggtgactc 360
tgctggacta cggcgccggg aacgtacgca gcgtgcgcaa cgcaattcgc tacctcggtc 420
tcgacatccg cgacgtgcag agcccggarg acatcgctgc cggcggaayg ggctgtcttt 480
cccgtgtcg gcgcnttcg ctccgccatg gacgtccnca ccaggacggg catgccaaac 540
cactccgtga gtacatccaa agggaaacgcc ctttcnagg cnetgcc 587

<210> 4
<211> 130
<212> PRT
<213> Zea mays

<220>
<221> UNSURE
<222> (90)

<220>
<221> UNSURE
<222> (93)

<220>
<221> UNSURE
<222> (109)

<220>
<221> UNSURE
<222> (115)

<220>
<221> UNSURE
<222> (129)

<400> 4
Met Gln Pro Pro Leu Gln Ala Gln Gly Ala Met Ala Asn Val Ala Ala
1 5 10 15
Ile Leu Thr Val Pro Cys Ser Ala Gly Arg Arg Pro Lys Arg Ser Asn
20 25 30
Gln Pro Arg Gly Cys Gly Ser Val Ser Val Ser Val Ser Val Arg Ala
35 40 45

Ser Ser Gly Ala Asn Thr Val Thr Leu Leu Asp Tyr Gly Ala Gly Asn
50 55 60

Val Arg Ser Val Arg Asn Ala Ile Arg Tyr Leu Gly Phe Asp Ile Arg
65 70 75 80

Asp Val Gln Ser Pro Glu Asp Ile Val Xaa Ala Glu Xaa Val Val Phe
85 90 95

Pro Gly Val Gly Ala Phe Gly Ser Ala Met Asp Val Xaa Thr Arg Thr
100 105 110

Gly Met Xaa Asn Ala Leu Arg Glu Tyr Ile Gln Arg Glu Arg Pro Phe
115 120 125

Xaa Gly
130

<210> 5
<211> 1084
<212> DNA
<213> Zea mays

<400> 5
actagtggta acaaaaggcg atcaatatga tgtaagagat catactagca gcaaagaggt 60
aagaaacctt ggcaagccag tcgatttagc aagccagtag tacatagacg gtgctgatga 120
ggtcagcttc ttgaatataa ctgggtttccg tgaatttcca ttgggtgatt tgccaatgct 180
agaggtactg cgttgtgcct ctgaaaagggt ttttgtgcc cttacagttg gtgggggcat 240
acgagacttc acagatgcaa atggaagata ctactcaagt ttggaggtag catcagaata 300
tttcaggtcc ggtgctgaca aaatttcaat tggaagtgat gctgtttatg ctgctgaagc 360
ctttttacag actggtgtaa agacagggaa aagcagcttg gagcaaatct cttagagtata 420
tggcaatcag gctgtagtgt tcagtattga tctctgacgg gtatatgtca aaagtcaaga 480
agatgtgcc tttaaaactg taaaggtgtc cactaaagggt ccatcgaggag aagaatatgc 540
atggtaccag tgcacagtga atggtggacg tgatagccga gctataggag catatgaact 600
agcgaaagct gtggaagaat tgggcgcagg agaaataact cttaactgca ttgattgtga 660
tggccaaggt tgtggatttg acatagattt gggttaaaatg gtttctgatg ctgtgacaat 720
ccctgtcatt gcgagcagtg gtgctggagc tgttcaacat ttttctgaaa tttttgagaa 780
aacaatgct tctgtgccc ttgctgctgg cattttccac cggaaagagg ttcctatact 840
agcagtgaag gagcatctgg tcaatgctgg tgtggaggtc aggggtgaac agggagatcc 900
ttcgggttat tgaaatattc ttgtttgatg tcacaactgc tatcagttct gtttctctga 960
tgtcgcaact gctatcagat ctgttggtgg cagctggcag tgcataggcc cctgtcgaga 1020
actgcagttt ggttaataat taataatgtg atgcttaaca gattaataaaa aaaaaaaaaa 1080
aaaa 1084

<210> 6
<211> 295
<212> PRT
<213> Zea mays

<400> 6
Leu Val Val Thr Lys Gly Asp Gln Tyr Asp Val Arg Asp His Thr Ser
1 5 10 15

Ser Lys Glu Val Arg Asn Leu Gly Lys Pro Val Asp Leu Ala Ser Gln
20 25 30

Tyr Tyr Ile Asp Gly Ala Asp Glu Val Ser Phe Leu Asn Ile Thr Gly
35 40 45

Phe Arg Asp Phe Pro Leu Gly Asp Leu Pro Met Leu Glu Val Leu Arg
50 55 60

Cys Ala Ser Glu Lys Val Phe Val Pro Leu Thr Val Gly Gly Gly Ile
65 70 75 80

Arg Asp Phe Thr Asp Ala Asn Gly Arg Tyr Tyr Ser Ser Leu Glu Val
85 90 95

Ala Ser Glu Tyr Phe Arg Ser Gly Ala Asp Lys Ile Ser Ile Gly Ser
100 105 110

Asp Ala Val Tyr Ala Ala Glu Ala Phe Leu Gln Thr Gly Val Lys Thr
115 120 125

Gly Lys Ser Ser Leu Glu Gln Ile Ser Arg Val Tyr Gly Asn Gln Ala
130 135 140

Val Val Val Ser Ile Asp Pro Arg Arg Val Tyr Val Lys Ser Gln Glu
145 150 155 160

Asp Val Pro Phe Lys Thr Val Lys Val Ser Thr Lys Gly Pro Ser Gly
165 170 175

Glu Glu Tyr Ala Trp Tyr Gln Cys Thr Val Asn Gly Gly Arg Asp Ser
180 185 190

Arg Ala Ile Gly Ala Tyr Glu Leu Ala Lys Ala Val Glu Glu Leu Gly
195 200 205

Ala Gly Glu Ile Leu Leu Asn Cys Ile Asp Cys Asp Gly Gln Gly Cys
210 215 220

Gly Phe Asp Ile Asp Leu Val Lys Met Val Ser Asp Ala Val Thr Ile
225 230 235 240

Pro Val Ile Ala Ser Ser Gly Ala Gly Ala Val Gln His Phe Ser Glu
245 250 255

Ile Phe Glu Lys Thr Asn Ala Ser Ala Ala Leu Ala Ala Gly Ile Phe
260 265 270

His Arg Lys Glu Val Pro Ile Leu Ala Val Lys Glu His Leu Val Asn
275 280 285

Ala Gly Val Glu Val Arg Val
290 295

<210> 7
<211> 494
<212> DNA
<213> Zea mays

<220>
<221> unsure
<222> (6)

<220>
<221> unsure
<222> (12)

[illegible]

<220>
<221> unsure
<222> (43)

<220>
<221> unsure
<222> (56)

<220>
<221> unsure
<222> (60)

<220>
<221> unsure
<222> (154)..(155)

<220>
<221> unsure
<222> (161)

<220>
<221> unsure
<222> (163)

<220>
<221> unsure
<222> (166)

<220>
<221> unsure
<222> (202)

<220>
<221> unsure
<222> (215)

<220>
<221> unsure
<222> (266)

<220>
<221> unsure
<222> (271)

<220>
<221> unsure
<222> (274)..(275)

<220>
<221> unsure
<222> (277)

<220>
<221> unsure
<222> (306)

<220>
<221> unsure
<222> (320)

<220>
<221> unsure
<222> (346)..(347)

<220>
<221> unsure
<222> (356)

<220>
<221> unsure
<222> (393)

<220>
<221> unsure
<222> (434)

<220>
<221> unsure
<222> (441)

<220>
<221> unsure
<222> (456)

<220>
<221> unsure
<222> (466)

<220>
<221> unsure
<222> (474)

<400> 7
tcgggncceg gngattcccg gggctcgagcc aacgggtccg gtnccctcaaa caaggncggg 60
catgggtcaac gcaactccggg ggagtatatc caagagggac cggccccttc ctaggcatct 120
gcctcggtct ccagctgctc ttcggattcc agcnnggaga nanggnccgt gtgagcggac 180
tcgggtgtgat atcaggcggtg gncaggcgat tcgantcctc aaatggcctc atagttccac 240
atgttggctg gaacgctctc cagatnacca nggnnanacc actgttgacg ggagctgatg 300
gccagnatgt gtacttttgn tcaactcctac cgcgtactgg cttcanngtg ctagnagga 360
aactgggggt tcctccatat ggcaactatg ggngacagct tttaatcctc catctcaaat 420
ggggcaacat tcanggcaag ntcaaatttc acccangaaa agagtnggaa gctnccccgg 480
actttcctat tcct 494

<210> 8
<211> 86
<212> PRT
<213> Zea mays

<220>
<221> UNSURE
<222> (23)

<220>
<221> UNSURE
<222> (25)..(26)..(27)

<220>
<221> UNSURE
<222> (39)

<220>
 <221> UNSURE
 <222> (43)

<220>
 <221> UNSURE
 <222> (60)

<220>
 <221> UNSURE
 <222> (62)..(63)..(64)

<220>
 <221> UNSURE
 <222> (74)

<220>
 <221> UNSURE
 <222> (78)

<400> 8
 Tyr Pro Arg Gly Thr Gly Pro Phe Leu Gly Ile Cys Leu Gly Leu Gln
 1 5 10 15
 Leu Leu Phe Gly Phe Gln Xaa Gly Xaa Xaa Xaa Arg Val Ser Gly Leu
 20 25 30
 Gly Val Ile Ser Gly Val Xaa Arg Arg Phe Xaa Ser Ser Asn Gly Leu
 35 40 45
 Ile Val Pro His Val Gly Trp Asn Ala Leu Gln Xaa Thr Xaa Xaa Xaa
 50 55 60
 Pro Leu Leu Gln Gly Ala Asp Gly Gln Xaa Val Tyr Phe Xaa His Ser
 65 70 75 80
 Tyr Arg Val Leu Ala Ser
 85

<210> 9
 <211> 495
 <212> DNA
 <213> Oryza sativa

<220>
 <221> unsure
 <222> (125)

<220>
 <221> unsure
 <222> (266)

<220>
 <221> unsure
 <222> (315)

<220>
 <221> unsure
 <222> (366)

<220>
<221> unsure
<222> (405)

<220>
<221> unsure
<222> (441)

<220>
<221> unsure
<222> (443)

<220>
<221> unsure
<222> (445)

<220>
<221> unsure
<222> (453)

<220>
<221> unsure
<222> (458)

<220>
<221> unsure
<222> (461)

<220>
<221> unsure
<222> (475)

<220>
<221> unsure
<222> (480)

<220>
<221> unsure
<222> (492)

<220>
<221> unsure
<222> (494)

<400> 9
gacacacacc cccatactg ccacaagggc cgcgcgcgc gccgggagcg atgggtcgccg 60
ccacctccat caacgccgtc ccctgctccg ctgggtcgcc gaagcggagg agccagcgcc 120
gcgngcctc tacggtcgcc gtgcgcgcgt ccggcgacgc tagcaccgtg acgctgctgg 180
actacggcgc gggcaacgtg cgcagcgtgc gcaatgccat ccgccacctc gggttcggca 240
tcgcgcgacgt gcgcagcccg gagganatcc tcgcgcgcga ccgcctcgtc ttcccggggg 300
tcggcgccctt cgggntcaag ccatggacgt cctcaaccgc ctccgggatg ggcggacgcg 360
cttcnccgga gtacatccgg caggggacgc ccccttcct cgggnatctg gccttcgggg 420
cttccaagct tctccttcgg nantnctaag ggnaaggnag naattggccc cggtnaggcn 480
gggcttgagg tntnt 495

<210> 10
<211> 87
<212> PRT
<213> Oryza sativa

<220>
 <221> UNSURE
 <222> (72)

<400> 10
 Met Val Ala Ala Thr Ser Ile Asn Ala Val Pro Cys Ser Ala Gly Arg
 1 5 10 15
 Pro Lys Arg Arg Ser Gln Arg Arg Gly Ala Ser Thr Val Ala Val Arg
 20 25 30
 Ala Ser Gly Asp Ala Ser Thr Val Thr Leu Leu Asp Tyr Gly Ala Gly
 35 40 45
 Asn Val Arg Ser Val Arg Asn Ala Ile Arg His Leu Gly Phe Gly Ile
 50 55 60
 Arg Asp Val Arg Ser Pro Glu Xaa Ile Leu Ala Ala Asp Arg Leu Val
 65 70 75 80
 Phe Pro Gly Val Gly Ala Phe
 85

<210> 11
 <211> 178
 <212> DNA
 <213> Glycine max

<400> 11
 ttgtgacttt gcttgattac ggtgctggca atgttcggag tgtcaggaat gcaatcagat 60
 tcctcgggtt tgacataaaa gatgtgcaaa ctccgcaaga tattctgaat gcaagtcggt 120
 tagtttttcc tgggtgttga gcatttgctg ctgccatgga ggtgttaagc aaaactgg 178

<210> 12
 <211> 58
 <212> PRT
 <213> Glycine max

<400> 12
 Val Thr Leu Leu Asp Tyr Gly Ala Gly Asn Val Arg Ser Val Arg Asn
 1 5 10 15
 Ala Ile Arg Phe Leu Gly Phe Asp Ile Lys Asp Val Gln Thr Pro Gln
 20 25 30
 Asp Ile Leu Asn Ala Ser Arg Leu Val Phe Pro Gly Val Gly Ala Phe
 35 40 45
 Ala Ala Ala Met Glu Val Leu Ser Lys Thr
 50 55

<210> 13
 <211> 671
 <212> DNA
 <213> Glycine max

<220>
 <221> unsure
 <222> (276)

<400> 13
 gtatgtaaag gatcctaatt atgtgcaatt gaagaccata aggggtttcaa gtccagggttc 60
 aaatggagag gaatatgcat ggtatcaatg tacagttaat gggggacgag agggccggcc 120
 aattggtgct tatgaactag caaaagcagt tgaagagctt ggtgctggtg aaatactact 180
 taattgcatt gattgcgacg gtcaagggaa aggatttgat gtagatttaa ttaagttgat 240
 atcaaagtct gtaagtatcc ctgttatcgc aagtancggt gctggtgctc ctgaacactt 300
 ctctgaggtg ttctataaaa caaatgcac agcagcactt gctgctggca tttttcacag 360
 gaaagaggtg cctattcagt cggtaaaaga gcatttggtg aaggaaggca tagaagttcg 420
 aatctgatca tatgcattta gtggtaaaat ttttgagatg cacttcataa taatcaaacc 480
 ttgtacgtta tccctttttg tgtaatctaa cgaagctctc aaaatgtcaa ccttttggtat 540
 catgaaaaga ttttcacaac gagaccttct ctttgtaata tttttaagga aaatatattt 600
 accatgtgca gcactatctc tgaacatttg ttattacaaa attatttcat gtgtcaaaaa 660
 aaaaaaaaaa a 671

<210> 14
 <211> 141
 <212> PRT
 <213> Glycine max

<220>
 <221> UNSURE
 <222> (92)

<400> 14
 Tyr Val Lys Asp Pro Asn Asp Val Gln Leu Lys Thr Ile Arg Val Ser
 1 5 10 15
 Ser Pro Gly Ser Asn Gly Glu Glu Tyr Ala Trp Tyr Gln Cys Thr Val
 20 25 30
 Asn Gly Gly Arg Glu Gly Arg Pro Ile Gly Ala Tyr Glu Leu Ala Lys
 35 40 45
 Ala Val Glu Glu Leu Gly Ala Gly Glu Ile Leu Leu Asn Cys Ile Asp
 50 55 60
 Cys Asp Gly Gln Gly Lys Gly Phe Asp Val Asp Leu Ile Lys Leu Ile
 65 70 75 80
 Ser Asn Ala Val Ser Ile Pro Val Ile Ala Ser Xaa Gly Ala Gly Ala
 85 90 95
 Pro Glu His Phe Ser Glu Val Phe Tyr Lys Thr Asn Ala Ser Ala Ala
 100 105 110
 Leu Ala Ala Gly Ile Phe His Arg Lys Glu Val Pro Ile Gln Ser Val
 115 120 125
 Lys Glu His Leu Leu Lys Glu Gly Ile Glu Val Arg Ile
 130 135 140

<210> 15
 <211> 593
 <212> PRT
 <213> Arabidopsis thaliana

<400> 15
 Met Glu Ala Thr Ala Ala Pro Phe Ser Ser Ile Val Ser Ser Arg Gln
 1 5 10 15

Asn Phe Ser Ser Ser Ser Ser Ile Arg Ala Ser Ser Pro Ala Ser Leu
20 25 30

Phe Leu Ser Gln Lys Ser Ile Gly Asn Val Asn Arg Lys Phe Lys Ser
35 40 45

Pro Arg Ser Leu Ser Val Arg Ala Ser Ser Thr Ser Asp Ser Val Val
50 55 60

Thr Leu Leu Asp Tyr Gly Ala Gly Asn Val Arg Ser Ile Arg Asn Ala
65 70 75 80

Leu Arg His Leu Gly Phe Ser Ile Lys Asp Val Gln Thr Pro Gly Asp
85 90 95

Ile Leu Asn Ala Asp Arg Leu Ile Phe Pro Gly Val Gly Pro Phe Ala
100 105 110

Pro Ala Met Asp Val Leu Asn Arg Thr Gly Met Ala Glu Ala Leu Cys
115 120 125

Lys Tyr Ile Glu Asn Asp Arg Pro Phe Leu Gly Ile Cys Leu Gly Leu
130 135 140

Gln Leu Leu Phe Asp Ser Ser Glu Gln Asn Gly Pro Val Lys Gly Leu
145 150 155 160

Gly Val Ile Pro Gly Ile Val Gly Arg Phe Asp Ala Ser Ala Gly Ile
165 170 175

Arg Val Pro His Ile Gly Trp Asn Ala Leu Gln Val Gly Lys Asp Ser
180 185 190

Glu Ile Leu Asp Asp Val Gly Asn Arg His Val Tyr Phe Val His Ser
195 200 205

Tyr Arg Ala Ile Pro Ser Asp Glu Asn Lys Asp Trp Ile Ser Ser Thr
210 215 220

Cys Asn Tyr Gly Glu Ser Phe Ile Ser Ser Ile Arg Arg Gly Asn Val
225 230 235 240

His Ala Val Gln Phe His Pro Glu Lys Ser Gly Glu Val Gly Leu Ser
245 250 255

Val Leu Arg Arg Phe Leu His Pro Lys Leu Pro Ala Thr Gln Lys Pro
260 265 270

Met Glu Gly Lys Ala Ser Lys Leu Ala Lys Arg Val Ile Ala Cys Leu
275 280 285

Asp Val Arg Thr Asn Asp Lys Gly Asp Leu Val Val Thr Lys Gly Asp
290 295 300

Gln Tyr Asp Val Arg Glu Gln Ser Asn Glu Asn Glu Val Arg Asn Leu
305 310 315 320

Gly Lys Pro Val Asp Leu Ala Gly Gln Tyr Tyr Lys Asp Gly Ala Asp
325 330 335

Glu Ile Ser Phe Leu Asn Ile Thr Gly Phe Arg Asp Phe Pro Leu Gly
 340 345 350
 Asp Leu Pro Met Ile Gln Val Leu Arg Gln Thr Ser Lys Asn Val Phe
 355 360 365
 Val Pro Leu Thr Val Gly Gly Gly Ile Arg Asp Phe Thr Asp Ala Ser
 370 375 380
 Gly Arg Tyr Tyr Ser Ser Leu Glu Val Ala Ala Glu Tyr Phe Arg Ser
 385 390 395 400
 Gly Ala Asp Lys Met Ser Ile Gly Ser Asp Ala Val Phe Ala Ala Glu
 405 410 415
 Glu Phe Ile Lys Ser Gly Val Lys Thr Gly Lys Ser Ser Leu Glu Gln
 420 425 430
 Ile Ser Arg Val Tyr Gly Asn Gln Ala Val Val Val Ser Ile Asp Pro
 435 440 445
 Arg Arg Val Tyr Val Asn His Pro Asp Asp Val Pro Tyr Lys Val Ile
 450 455 460
 Arg Val Thr Asn Pro Gly Pro Asn Gly Glu Glu Tyr Ala Trp Tyr Gln
 465 470 475 480
 Cys Thr Val Ser Gly Gly Gln Glu Gly Arg Pro Ile Gly Ala Phe Glu
 485 490 495
 Leu Ala Lys Ala Val Glu Glu Leu Gly Ala Gly Glu Ile Leu Leu Asn
 500 505 510
 Cys Ile Asn Cys Asp Gly Gln Gly Lys Gly Phe Asp Ile Asp Leu Val
 515 520 525
 Lys Leu Ile Ser Asp Ser Val Gly Ile Pro Val Ile Ala Ser Ser Gly
 530 535 540
 Ala Gly Thr Pro Asp His Phe Ser Glu Val Phe Glu Glu Asp Lys Arg
 545 550 555 560
 Ile Cys Arg Ala Cys Cys Arg His Phe Pro Pro Glu Arg Gly Tyr Gln
 565 570 575
 Ser Gln Ser Val Lys Glu His Leu Gln Glu Glu Arg Ile Glu Val Arg
 580 585 590
 Ile

TITLEPLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS

5

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding a histidine biosynthetic protein in plants and seeds.

BACKGROUND OF THE INVENTION

10 Histidine biosynthesis begins with condensation of ATP with phosphoribosyl pyrophosphate (PRPP) to form N¹-(5'-phosphoribosyl)-ATP. Imidazole glycerol phosphate (IGP) synthase, a heterodimeric enzyme consisting of the *hisF* and *hisH* gene products, catalyzes the fifth step of histidine biosynthesis, wherein phosphoribulosyl formimino-5-aminoimidazole-4-carboxamide ribonucleotide (PRFAR) and glutamine are transformed into
15 glutamate, IGP and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). This reaction is of the glutamine amidotransferase class. AICAR is a purine biosynthetic intermediate; thus there is a linkage between the purine and histidine biosynthetic pathways such that the purine ring removed in the first step of the histidine pathway is replenished by the couple between the reaction catalyzed by IGP synthase and the purine biosynthetic
20 pathway.

It has been shown in a number of systems that missense mutations that decrease, but do not eliminate, the catalytic efficiency of the fourth step (formation of PRFAR from Pro-phosphoribosyl formimino-5-aminoimidazole-4-carboxamide ribonucleotide or 5'-ProFAR, catalyzed by 5'-ProFAR isomerase, the product of the *hisA* gene) or fifth step of
25 histidine biosynthesis result in a biosynthetic limitation that is overcome by (a) histidine, (b) adenine or (c) a false feedback inhibitor of the first step of the histidine pathway (Hartman et al. (1960) *J. Gen. Microbiol.* 22:323; Shedlovsky and Magasanik (1962) *J. Biol. Chem.* 237:3725; Shedlovsky and Magasanik (1962) *J. Biol. Chem.* 237:3731; Galloway and Taylor (1980) *J. Bacteriol.* 144:1068; Shioi et al. (1982) *J. Biol. Chem.* 257:7969; Burton (1955) *Biochem. J.* 61:473; Burton (1957) *Biochem. J.* 66:488; Stougaard and Kennedy (1988) *J. Bacteriol.* 170:250). This result indicates that a high level flux through the partially blocked histidine biosynthetic pathway results in an ATP (energy) drain. Such blockage has been shown to have unique, deleterious pleiotropic effects upon a diversity of energy-intensive microbial processes including chemotaxis (Galloway and Taylor (1980) *J. Bacteriol.* 144:1068), DNA replication (Burton (1955) *Biochem. J.* 61:473; Burton (1957) *Biochem. J.* 66:488) and nitrogen fixation (Stougaard and Kennedy (1988) *J. Bacteriol.* 170:250). In each interrupted process, activity is restored by (a) histidine, (b) adenine or
35 (c) a false feedback inhibitor of the first step in histidine biosynthesis.

These studies strongly suggest that enzymes encoded by the *hisA*, *hisF* or *hisH* genes will be useful for discovering herbicides and fungicides. The discovery of homologous biosynthetic pathways and corresponding enzymes in plants and fungi indicates that inhibition of such enzymes would be viable strategies for herbicidal control of unwanted vegetation and fungicidal control of plant disease. For example, inhibition of the fourth and fifth steps of histidine biosynthesis will result in the specific draining of the ATP pool to levels significantly lower than normal (Johnson and Taylor (1993) *Applied Environ. Microbiol.* 59:3509). This specific drain is achieved by having the histidine synthetic pathway operating at a high, near maximal, rate through the relief from allosteric feedback inhibition of the *hisG*-encoded enzyme, ATP phosphoribosyl transferase. By preventing the release of AICAR by the IGP synthase, the adenylate pool is drained. Although energy homeostasis can be maintained by simply rephosphorylation of the adenylate to a high energy state, inhibition of the *hisHF* or *hisA* encoded enzymes traps the adenylate as histidine biosynthetic intermediates. Accordingly, lowered flux through the enzymes encoded by *hisA* and *hisHF* will cripple the cell's ability to carry out necessary metabolic processes.

Moreover, interruption of other steps in the histidine biosynthetic pathway in plants may also result in plant growth inhibition or death. For example, decrease or elimination of histidinol phosphate aminotransferase encoded by a plant homolog of *hisC* may inhibit conversion of glutamate to α -ketoglutarate and thereby have a detrimental effect on plant growth and development. The enzyme encoded by *hisB* is in part responsible for catalyzing the seventh and ninth steps of the histidine biosynthetic pathway. In the seventh step of the pathway D-erythro-1-(imidazol-4-yl)glycerol 3-phosphate is converted to 3-(imidazol-4-yl)-2-oxopropyl phosphate by HisB. In the ninth step of the pathway histidinol phosphate is converted to histidinol by the action of HisB. Very little is known about HisB activity in plants, however, because this enzyme catalyzes two steps in the pathway. Interruption of HisB activity could severely alter normal histidine biosynthesis. Lastly, interruption of histidinol dehydrogenase activity (encoded by a homolog of the *hisD* gene), the enzyme that catalyzes the final step in the pathway, would prevent the formation of histidine. Finally, since the biosynthesis of histidine is energetically costly to the cell, inhibition of transformations at the later steps in the pathway would consume significant cellular energy resources without the formation of the expected end product, thus placing the affected cell at a disadvantage.

Thus, availability of the genes and their encoded enzymes has utility for herbicide and fungicide discovery via the design and implementation of cell-based screening and assay methodologies, enzyme-based screening and assay methodologies, rationale inhibitor design, x-ray crystallography, combinatorial chemistry and other modern biochemical and biotechnological methods.

SUMMARY OF THE INVENTION

The present invention relates to isolated polynucleotides comprising a nucleotide sequence encoding a first polypeptide of at least 60 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of an impatiens glutamine amidotransferase homolog of SEQ ID NO:2, corn glutamine amidotransferase homolog polypeptide of SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:8, a rice glutamine amidotransferase homolog polypeptide of SEQ ID NO:10, a soybean glutamine amidotransferase homolog polypeptide of SEQ ID NO:12 or SEQ ID NO:14. The present invention also relates to an isolated polynucleotide comprising the complement of the nucleotide sequences described above.

It is preferred that the isolated polynucleotide of the claimed invention consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14. The present invention also relates to an isolated polynucleotide comprising a nucleotide sequences of at least one of 40 (preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, and the complement of such nucleotide sequences.

The present invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to suitable regulatory sequences.

The present invention relates to an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

The present invention relates to a process for producing an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention, the process comprising either transforming or transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

The present invention relates to a glutamine amidotransferase homolog polypeptide of at least 60 amino acids comprising at least 85% homology based on the Clustal method of alignment compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14.

The present invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a glutamine amidotransferase homolog polypeptide in a host cell, preferably a plant cell, the method comprising the steps of:

constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention;

introducing the isolated polynucleotide or the isolated chimeric gene into a host cell;

measuring the level a glutamine amidotransferase homolog polypeptide in the host cell containing the isolated polynucleotide; and

- 5 comparing the level of a glutamine amidotransferase homolog polypeptide in the host cell containing the isolated polynucleotide with the level of a glutamine amidotransferase homolog polypeptide in a host cell that does not contain the isolated polynucleotide.

10 The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a glutamine amidotransferase homolog polypeptide gene, preferably a plant glutamine amidotransferase homolog polypeptide gene, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ
15 ID NOs:1, 3, 5, 7, 9, 11, 13, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a glutamine amidotransferase homolog amino acid sequence.

20 The present invention also relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a glutamine amidotransferase homolog polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the
25 isolated DNA clone.

 A further embodiment of the instant invention is a method for evaluating at least one compound for its ability to inhibit the activity of a glutamine amidotransferase homolog, the method comprising the steps of: (a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding a glutamine amidotransferase homolog,
30 operably linked to suitable regulatory sequences; (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of glutamine amidotransferase homolog in the transformed host cell; (c) optionally purifying the glutamine amidotransferase homolog expressed by the transformed host cell; (d) treating the glutamine amidotransferase homolog
35 with a compound to be tested; and (e) comparing the activity of the glutamine amidotransferase homolog that has been treated with a test compound to the activity of an untreated glutamine amidotransferase homolog, thereby selecting compounds with potential for inhibitory activity.

WO 00/28053

PCT/US99/25950

The present invention relates to a composition comprising an isolated polynucleotide of the present invention.

The present invention relates to an isolated polynucleotide of the present invention comprising the nucleotide sequence comprising at least one of 30 contiguous nucleotides of a nucleic sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13.

The present invention relates to an expression cassette comprising an isolated polynucleotide of the present invention operably linked to a promoter.

The present invention relates to a method for positive selection of a transformed cell comprising:

(a) transforming a plant cell with the chimeric gene of the present invention or an expression cassette of the present invention; and

(b) growing the transformed plant cell, preferably a monocot such as corn, under conditions allowing expression of the polynucleotide in an amount sufficient to complement a histidine biosynthetic auxotroph to provide a positive selection means.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTING

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

Figure 1 shows a comparison of the amino acid sequences of the *Arabidopsis thaliana* glutamine amidotransferase protein having NCBI General Identifier No. 3219164 (SEQ ID NO:15) and the amino acid sequence encoded by the cDNA insert in clone ids.pk0024.c4 (SEQ ID NO:2) encoding an entire glutamine amidotransferase (HisHF) and the amino acid sequences encoding partial glutamine amidotransferases (HisHF) from corn contig assembled from clones cpe1c.pk012.c10, p0010.cbpbq28r, and p0131.ccdap46r (SEQ ID NO:4), corn contig assembled from clones cco1n.pk071.i21, cco1n.pk071.i21:fis, cpj1c.pk005.p14, p0016.ctscc75r, and rlr48.pk0001.f5 (SEQ ID NO:6), corn clone p0119.cmtnx82r (SEQ ID NO:8), rice clone rr1.pk094.n24 (SEQ ID NO:10), soybean clone sdp4c.pk002.n13 (SEQ ID NO:12), and a soybean contig assembled from clones sl1.pk152.c18, sl1.pk152.c18:fis, and src3c.pk022.b14 (SEQ ID NO:14). The predicted CTP cleavage site is indicated with an arrow above the sequences, the carbamoyl-phosphate synthase protein GATASE domain signature E motif 2 and the GATASE type 1 motif are boxed. The location of the amino acids which were mutagenized without effect on the enzyme are indicated by a gray box and white letters. Dashes are used by the program to maximize the alignment.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as

used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

5

TABLE 1
Histidine Biosynthetic Enzyme

Protein	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Impatiens Glutamine Amidotransferase (HisHF)	ids.pk0024.c4:fis	1	2
Corn Glutamine Amidotransferase (HisHF)	Contig of: cpe1c.pk012.c10 p0010.cbpbq28r p0131.ccdap46r	3	4
Corn Glutamine Amidotransferase (HisHF)	Contig of: cco1n.pk071.i21 cco1n.pk071.i21:fis cpj1c.pk005.p14 p0016.ctscc75r rlr48.pk0001.f5*	5	6
Corn Glutamine Amidotransferase (HisHF)	p0119.cmtnx82r	7	8
Rice Glutamine Amidotransferase (HisHF)	rr1.pk094.n24	9	10
Soybean Glutamine Amidotransferase (HisHF)	sdp4c.pk002.n13	11	12
Soybean Glutamine Amidotransferase (HisHF)	Contig of: sl1.pk152.c18 sl1.pk152.c18:fis src3c.pk022.b14	13	14

*clone rlr48.pk0001.f5 is in reality a corn clone which was misidentified at the lab.

10 The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

15 Polynucleotide sequences encoding portions of Glutamine amidotransferases (HisHF) polypeptides from corn (derived from clone ccase-b.pk0024.b9 and a contig assembled from clones cco1n.pk071.i21 and cen3n.pk0211.e9), *Impatiens* (derived from clone ids.pk0024.c4), and soybean (derived from clones sdp4c.001.e7 and sdp4c.pk002.n13) are

found in U.S. Provisional Application No. 60/107,275, filed November 5, 1998, incorporated herein by reference.

DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. As used herein, a
5 “polynucleotide” is a nucleotide sequence such as a nucleic acid fragment. A polynucleotide
may be a polymer of RNA or DNA that is single- or double-stranded, that optionally
contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of
a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, or
synthetic DNA. An isolated polynucleotide of the present invention may include at least one
10 of 60 contiguous nucleotides, preferably at least one of 40 contiguous nucleotides, most
preferably one of at least 30 contiguous nucleotides, of the nucleic acid sequence of the SEQ
ID NOs:1, 3, 5, 7, 9, 11, and 13.

As used herein, “contig” refers to a nucleotide sequence that is assembled from two or
more constituent nucleotide sequences that share common or overlapping regions of
15 sequence homology. For example, the nucleotide sequences of two or more nucleic acid
fragments can be compared and aligned in order to identify common or overlapping
sequences. Where common or overlapping sequences exist between two or more nucleic
acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be
assembled into a single contiguous nucleotide sequence.

20 As used herein, “substantially similar” refers to nucleic acid fragments wherein
changes in one or more nucleotide bases results in substitution of one or more amino acids,
but do not affect the functional properties of the polypeptide encoded by the nucleotide
sequence. “Substantially similar” also refers to nucleic acid fragments wherein changes in
one or more nucleotide bases does not affect the ability of the nucleic acid fragment to
25 mediate alteration of gene expression by gene silencing through for example antisense or co-
suppression technology. “Substantially similar” also refers to modifications of the nucleic
acid fragments of the instant invention such as deletion or insertion of one or more
nucleotides that do not substantially affect the functional properties of the resulting
transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional
30 properties of the resulting protein molecule. It is therefore understood that the invention
encompasses more than the specific exemplary nucleotide or amino acid sequences and
includes functional equivalents thereof.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid
fragments representing subfragments or modifications of the nucleic acid fragments of the
35 instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted,
for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid
fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment
representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid

fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic acid fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of a polypeptide in a plant cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide (such as amido glutamine amidotransferase) in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial, or viral) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide in the host cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press,

Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions

5 uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C.

10 Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by

15 those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least 70%, preferably at least 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are at least 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that

20 are at least 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more

25 preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP

30 PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein

35 or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see

also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes

5 comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a

10 nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed

15 sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded

20 polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell,

25 it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which

30 may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized", as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly,

35 the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards

those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences

have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

The "translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

“Antisense inhibition” refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. “Overexpression” refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. “Co-suppression” refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

“Altered levels” refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

“Mature” protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. “Precursor” protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A “chloroplast transit peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. “Chloroplast transit sequence” refers to a nucleotide sequence that encodes a chloroplast transit peptide. A “signal peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).

Nucleic acid fragments encoding at least a portion of several histidine biosynthetic enzymes have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST

algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other glutamine amidotransferase homologs, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably one of at least 40, most preferably one of at least 30) contiguous nucleotides derived from a nucleotide sequence selected from the

group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide. The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a polypeptide of a gene (such as a glutamine amidotransferase homolog) preferably a substantial portion of a plant polypeptide of a gene, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a polypeptide.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

The nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of histidine biosynthesis in those cells.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric gene can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and

thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

5 For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate their secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by altering the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or
10 sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

15 It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the
20 instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression
25 have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of
30 gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant
35 gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require

WO 00/28053

PCT/US99/25950

acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger

and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLE 1

Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various impatiens, corn, rice, and soybean tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Impatiens, Corn, Rice, and Soybean

Library	Tissue	Clone
cco1n	Corn Cob of 67 Day Old Plants Grown in Green House ^a	cco1n.pk071.i21
cpe1c	Corn pooled BMS treated with chemicals related to phosphatase ^b	cpe1c.pk012.c10
cpj1c	Corn Pooled BMS Treated With Chemicals Related to Membrane Ionic Force ^c	cpj1c.pk005.p14
ids	<i>Impatiens balsamia</i> Developing Seed	ids.pk0024.c4
p0010	Corn Log Phase Suspension Cells Treated With A23187 ^d to Induce Mass Apoptosis	p0010.cbpbq28r

Library	Tissue	Clone
p0016	Corn Tassel Shoots, Pooled, 0.1-1.4 cm	p0016.ctscc75r
p0119	Corn V12-Stage ^e Ear Shoot With Husk, Night Harvested ^a	p0119.cmtnx82r
p0131	Transformed Callus Tissue ^a	p0131.ccdap46r
cen3n ^f	Corn Endosperm 20 Days After Pollination ^a	rlr48.pk0001.f5
rr1	Rice Root of Two Week Old Developing Seedling	rr1.pk094.n24
sdp4c	Soybean Developing Pods (10-12 mm)	sdp4c.pk002.n13
sl1	Soybean Two-Week-Old Developing Seedlings	sl1.pk152.c18
sl1	Soybean Two-Week-Old Developing Seedlings	sl1.pk152.c18
src3c	Soybean 8 Day Old Root Infected With Cyst Nematode	src3c.pk022.b14

^a These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

^b Chemicals used included okadaic acid, cyclosporin A, calyculin A, cypermethrin.

5 ^c Chemicals used included valinomycin, bafilomycin A1, oligomycin, ionomycin.

^d A23187 is commercially available from several vendors including Calbiochem.

^e Corn developmental stages are explained in the publication "How a corn plant develops" from the Iowa State University Coop. Ext. Service Special Report No. 48 reprinted June 1993.

10 ^f This clone was mislabeled during processing. It belongs to the cen3n library even though it is labeled as a rlr48 clone.

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA
 15 libraries in Uni-ZAPTM XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAPTM XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA
 20 ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via
 25 polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

EXAMPLE 2

Identification of cDNA Clones

cDNA clones encoding histidine biosynthetic enzymes were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

EXAMPLE 3

Characterization of cDNA Clones Encoding Glutamine Amidotransferase

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptide with similarity to glutamine amidotransferase/cyclase obtained from the translation of the EU *Arabidopsis thaliana* sequencing project (NCBI General Identifier No. 4455213) and to the glutamine amidotransferase/cyclase from *Arabidopsis thaliana* (NCBI General Identifier No. 3219164). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), contigs assembled from two or more ESTs ("Contig"), contigs assembled from the sequence of the entire cDNA insert comprising the indicated cDNA clones ("FIS") and one or more ESTs ("Contig*"), or sequences encoding the entire protein derived from an FIS ("CGS"):

TABLE 3

BLAST Results for Sequences Encoding Polypeptides Homologous
to Glutamine Amidotransferase

Clone	Status	BLAST pLog Score	
		4455213	3219164
ids.pk0024.c4	CGS	254.00	254.00
Contig of: cpe1c.pk012.c10 p0010.cbpbq28r p0131.ccdap46r	Contig	21.00	20.40
Contig of: cco1n.pk071.i21 cpj1c.pk005.p14 p0016.ctscc75r rlr48.pk0001.f5	Contig*	163.00	149.00
p0119.cmtnx82r	EST	13.00	13.00
rr1.pk094.n24	EST	19.20	18.50
sdp4c.pk002.n13	EST	25.40	24.70
Contig of: sl1.pk152.c18 sl1.pk152.c18 src3c.pk022.b14	Contig*	76.20	58.40

- 5 Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID NO:2 and the *Arabidopsis thaliana* sequence (SEQ ID NO:15). Indicated with an arrow above the sequences is the location of the predicted CTP cleavage site. Boxed are the carbamoyl-phosphate synthase protein GATASE domain signature E motif 2 (probably containing the active Cysteine) and the GTASE type 1 domain. An asterisk above the alignment indicates those amino acids conserved among both sequences. An x above the sequence indicates 10 amino acids which when mutated diminish the function of the enzymes and an equal sign (=) above the alignment indicates the amino acids which when mutated do not appear to effect the activity of the enzyme.

- 15 The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14 and the *Arabidopsis thaliana* sequence (SEQ ID NO:15).

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to Glutamine Amidotransferase

SEQ ID NO.	Percent Identity to 3219164
2	72.9
4	44.6
6	72.5
8	46.5
10	47.1
12	79.3
14	66.7

5 Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of one impatiens, three corn, one rice and two soybean glutamine amidotransferase. These sequences represent the first monocot, *impatiens*, and soybean sequences encoding glutamine amidotransferase.

EXAMPLE 4

Expression of Chimeric Genes in Monocot Cells

20 A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. 25 Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest 30 Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas,

WO 00/28053

PCT/US99/25950

VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles

WO 00/28053

PCT/US99/25950

resuspended in a final volume of 30 μ L of ethanol. An aliquot (5 μ L) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains gluphosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing gluphosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

EXAMPLE 5

Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described

WO 00/28053

PCT/US99/25950

above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al.(1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µl spermidine (0.1 M), and 50 µL CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the

WO 00/28053

PCT/US99/25950

retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 6

Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides

are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio- β -galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 μ L of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One μ g of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

EXAMPLE 7

Evaluating Compounds for Their Ability to Inhibit the Activity of a Histidine Biosynthetic Enzyme

The polypeptides described herein may be produced using any number of methods known to those skilled in the art. Such methods include, but are not limited to, expression in bacteria as described in Example 6, or expression in eukaryotic cell culture, *in planta*, and using viral expression systems in suitably infected organisms or cell lines. The instant polypeptides may be expressed either as mature forms of the proteins as observed *in vivo* or as fusion proteins by covalent attachment to a variety of enzymes, proteins or affinity tags. Common fusion protein partners include glutathione S-transferase ("GST"), thioredoxin ("Trx"), maltose binding protein, and C- and/or N-terminal hexahistidine polypeptide ("His)₆"). The fusion proteins may be engineered with a protease recognition site at the fusion point so that fusion partners can be separated by protease digestion to yield intact mature enzyme. Examples of such proteases include thrombin, enterokinase and factor Xa. However, any protease can be used which specifically cleaves the peptide connecting the fusion protein and the enzyme.

Purification of the instant polypeptides, if desired, may utilize any number of separation technologies familiar to those skilled in the art of protein purification. Examples of such methods include, but are not limited to, homogenization, filtration, centrifugation, heat denaturation, ammonium sulfate precipitation, desalting, pH precipitation, ion exchange chromatography, hydrophobic interaction chromatography and affinity chromatography, wherein the affinity ligand represents a substrate, substrate analog or inhibitor. When the instant polypeptides are expressed as fusion proteins, the purification protocol may include

the use of an affinity resin which is specific for the fusion protein tag attached to the expressed enzyme or an affinity resin containing ligands which are specific for the enzyme. For example, the instant polypeptides may be expressed as a fusion protein coupled to the C-terminus of thioredoxin. In addition, a (His)₆ peptide may be engineered into the

5 N-terminus of the fused thioredoxin moiety to afford additional opportunities for affinity purification. Other suitable affinity resins could be synthesized by linking the appropriate ligands to any suitable resin such as Sepharose-4B. In an alternate embodiment, a thioredoxin fusion protein may be eluted using dithiothreitol; however, elution may be accomplished using other reagents which interact to displace the thioredoxin from the resin.

10 These reagents include β -mercaptoethanol or other reduced thiol. The eluted fusion protein may be subjected to further purification by traditional means as stated above, if desired. Proteolytic cleavage of the thioredoxin fusion protein and the enzyme may be accomplished after the fusion protein is purified or while the protein is still bound to the ThioBond™ affinity resin or other resin.

15 Crude, partially purified or purified enzyme, either alone or as a fusion protein, may be utilized in assays for the evaluation of compounds for their ability to inhibit enzymatic activation of the instant polypeptides disclosed herein.

EXAMPLE 8

Development of an Assay to Measure the Activity of a Histidine Biosynthetic Enzyme

Measurement of the optimal activity of histidine biosynthetic enzymes may be accomplished by suppression of the His auxotrophy of corresponding *Escherichia coli* hisH and hisF mutants. An assay was developed for in vitro analysis of HisHF activity. The substrate for HisHF, PRFAR [(N¹-[(5'-phosphoribulosyl) formimino]-5-aminoimidazole-4-

25 carboxamide ribonucleotide)], was synthesized by an enzymatic reaction of ATP and PRPP (phosphoribosyl pyrophosphate). The reaction is catalyzed by a mixture of the enzymes including *HisA*, *HisG*, *HisI*, which catalyze the first four steps in histidine biosynthesis pathway leading to the formation of PRFAR. PRFAR was purified by Q-Sepharose chromatography followed by HPLC using a C₁₈ column. Purified PRFAR has the expected

30 UV spectrum with major peak at OD₂₉₀.

The HisHF catalyzed conversion of PRFAR to AICAR and IGP is monitored at O.D.₃₀₀ for the decrease of PRFAR level. The optimized buffer condition was determined to be 15 mM KPi, pH 7.5, 5 mM Glutamine, 100 uM PRFAR. The steady state kinetic constants were determined for HisHF by varying the concentration of PRFAR or glutamine,

35 the two substrates for the reaction.

EXAMPLE 9Determination of Amino Acids Essential for
Histidine Biosynthetic Enzyme Activity

Site-directed mutagenesis of the HisHF enzyme allows the determination of the amino acids essential for activity and catalysis. Site-directed mutagenesis was carried out for, both, the hisH domain (glutamine amidotransferase) and the hisF domain (cyclase). Based on sequence homology with other trpG-type glutamine amidotransferases and the cysteine protease family, three conserved residues in the hisH domain that constitute the putative "catalytic triad" for the glutamine amidotransfer step were mutagenized. The mutants (based on the Arabidopsis thaliana sequence, SEQ ID NO:15) include Cys141→Ala or Ser; His246→Ala; Glu248→Ala or Gln. All of the hisH-domain mutants were constructed by gap repair recombination and found to be unable to complement the yeast mutant strain ZXY72-1B indicating that these residues are probably essential for the function of the glutamine amidotransferase domain, consistent with their proposed role in the putative catalytic triad.

Little biochemical study has been done for the F domain of HisHF enzyme. HisF shares a low level homology to HisA enzyme, the 5'-PRFAR isomerase which catalyzes the enzymatic step before hisF. Based on the sequence homology between yeast HisHF and other HisF proteins, we identified a group of highly conserved charged residues that are likely to be important for substrate binding or catalysis for the cyclase reaction, which involves an abstraction of a proton to give the product IGP (imidazole glycerol phosphate). An alanine scanning approach was undertaken for these conserved residues, the mutant clones were studied for complementation of yeast strain ZXY72-1B. The hisF domain mutants were constructed by gap repair recombination, similar to the construction of hisH domain mutants. Mutations were Lys302→Ala, Asp334→Ala, Glu336→Ala, Asp403→Ala, Lys404→Ala, Ser409→Ala, Asp447→Ala, Glu508→Ala, Asp517→Ala, and Glu553→Ala. Of these Asp403, Lys404, Asp447, Glu508, and Asp517 are unable to complement the yeast strain ZXY72-1B suggesting that they are essential for enzyme activity.

CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence encoding a first polypeptide of at least 60 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a histidine biosynthetic enzyme polypeptide of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14, or an isolated polynucleotide comprising the complement of the nucleotide sequence.
2. The isolated polynucleotide of Claim 1, wherein the isolated nucleotide sequence consists of a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14.
3. The isolated polynucleotide of Claim 1 wherein the nucleotide sequence is DNA.
4. The isolated polynucleotide of Claim 1 wherein the nucleotide sequence is RNA.
5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably linked to suitable regulatory sequences.
6. An isolated host cell comprising the chimeric gene of Claim 5.
7. An isolated host cell comprising an isolated polynucleotide of Claim 1.
8. The isolated host cell of Claim 7 wherein the isolated host is selected from the group consisting of yeast, bacteria, plant, and virus.
9. A virus comprising the isolated polynucleotide of Claim 1.
10. A polypeptide of at least 60 amino acids that has at least 85% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of a histidine biosynthetic enzyme polypeptide of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14.
11. A method of selecting an isolated polynucleotide that affects the level of expression of a histidine biosynthetic enzyme polypeptide in a plant cell, the method comprising the steps of:
 - (a) constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from an isolated polynucleotide of Claim 1;
 - (b) introducing the isolated polynucleotide into a plant cell;
 - (c) measuring the level of a glutamine amidotransferase polypeptide in the plant cell containing the polynucleotide; and
 - (d) comparing the level of a glutamine amidotransferase polypeptide in the plant cell containing the isolated polynucleotide with the level of a glutamine amidotransferase polypeptide in a plant cell that does not contain the isolated polynucleotide.

WO 00/28053

PCT/US99/25950

12. The method of Claim 11 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 14.

13. A method of selecting an isolated polynucleotide that affects the level of expression of a histidine biosynthetic enzyme polypeptide in a plant cell, the method comprising the steps of:

- (a) constructing an isolated polynucleotide of Claim 1;
- (b) introducing the isolated polynucleotide into a plant cell;
- (c) measuring the level of a glutamine amidotransferase polypeptide in the plant cell containing the polynucleotide; and
- (d) comparing the level of a glutamine amidotransferase polypeptide in the plant cell containing the isolated polynucleotide with the level of a glutamine amidotransferase polypeptide in a plant cell that does not contain the polynucleotide.

14. A method of obtaining a nucleic acid fragment encoding a histidine biosynthetic enzyme polypeptide comprising the steps of:

- (a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13 and the complement of such nucleotide sequences; and
- (b) amplifying a nucleic acid sequence using the oligonucleotide primer.

15. A method of obtaining a nucleic acid fragment encoding the amino acid sequence encoding a histidine biosynthetic enzyme polypeptide comprising the steps of:

- (a) probing a cDNA or genomic library with an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13 and the complement of such nucleotide sequences;
- (b) identifying a DNA clone that hybridizes with the isolated polynucleotide;
- (c) isolating the identified DNA clone; and
- (d) sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

16. A method for evaluating at least one compound for its ability to inhibit the activity of a histidine biosynthetic enzyme, the method comprising the steps of:

- (a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding a histidine biosynthetic enzyme, operably linked to suitable regulatory sequences;
- (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in

WO 00/28053

PCT/US99/25950

production of the histidine biosynthetic enzyme encoded by the operably linked nucleic acid fragment in the transformed host cell;

(c) optionally purifying the histidine biosynthetic enzyme expressed by the transformed host cell;

5 (d) treating the histidine biosynthetic enzyme with a compound to be tested; and

(e) comparing the activity of the histidine biosynthetic enzyme that has been treated with a test compound to the activity of an untreated histidine biosynthetic enzyme, thereby selecting compounds with potential for inhibitory activity.

17. A composition comprising an isolated polynucleotide of Claim 1.

10 18. A composition comprising an isolated polypeptide of Claim 10.

19. An isolated polynucleotide of Claim 1 comprising the nucleotide sequence comprising at least one of 30 contiguous nucleotides of a nucleic sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, and 13.

15 20. An expression cassette comprising an isolated polynucleotide of Claim 1 operably linked to a promoter.

21. A method for positive selection of a transformed cell comprising:

(a) transforming a plant cell with the chimeric gene of Claim 5 or an expression cassette of Claim 20; and

20 (b) growing the transformed plant cell under conditions allowing expression of the polynucleotide in an amount sufficient to complement a histidine biosynthetic auxotroph to provide a positive selection means.

22. The method of Claim 21 wherein the plant cell is a monocot.

23. The method of Claim 22 wherein the monocot is corn.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/82, 15/52, 9/00, 5/10, G01N 33/50, C12Q 1/68		A3	(11) International Publication Number: WO 00/28053
			(43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/25950 (22) International Filing Date: 4 November 1999 (04.11.99) (30) Priority Data: 60/107,275 5 November 1998 (05.11.98) US (71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ALLEN, Stephen, M. [US/US]; 2225 Rosewood Drive, Wilmington, DE 19810 (US). HUANG, Lisa, L. [CN/US]; 1423 Old Wilmington Road, Hockessin, DE 19707 (US). FALCO, Saverio, Carl [US/US]; 1902 Millers Road, Arden, DE 19810 (US). RAFALSKI, Antoni, J. [US/US]; 2028 Longcome Drive, Wilmington, DE 19810 (US). (74) Agent: FEULNER, Gregory, J.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 17 August 2000 (17.08.00)	
(54) Title: PLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS			
SEQ ID NO:15 GIPVIASSGAGTPDHFSEVFEEEDKRICRACCRHFPPERGYQSQSVKEHLQEERIEVRI SEQ ID NO:02 NIPVIASSGAGVADHFSEVFNETNASAALAAGIFHR-KEVPIKAVKEHLLKEGIEVRL SEQ ID NO:04 ----- SEQ ID NO:08 ----- SEQ ID NO:06 TIPVIASSGAGAVQHFSEIFEKTNASAALAAGIFHR-KEVPILAVKEHLVNAGVEVRV SEQ ID NO:10 ----- SEQ ID NO:12 ----- SEQ ID NO:14 SIPVIASXGAGAPEHFSEVFYKTNASAALAAGIFHR-KEVPIQSVKEHLLKEGIEVRI 541 598			
(57) Abstract <p>This invention relates to an isolated nucleic acid fragment encoding a histidine biosynthetic enzyme. The invention also relates to the construction of a chimeric gene encoding all or a portion of the histidine biosynthetic enzyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the histidine biosynthetic enzyme in a transformed host cell.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

▶

 $\frac{1}{4}$

09/831233

FIGURE 1

SEQ ID NO:15	VPHIGWNAIQVKDSEILDDVGNRHVYFVHSYRAIPSDENKDWISSTCNYESFISSIR	
SEQ ID NO:02	VPHIGWHALDIKEGSAILDDVGNQHVYFVHSYRA-NAEDNKEWISSSTCSYGDDFIASIQK	
SEQ ID NO:04	-----	
SEQ ID NO:08	VPHVGWNAIQXTXXXPLQAGDGQXVYFXHSYRVLAS	
SEQ ID NO:06	-----	
SEQ ID NO:10	-----	
SEQ ID NO:12	-----	
SEQ ID NO:14	-----	240
		181
SEQ ID NO:15	GN VHAVQFHPE KSGEVGLSVLRRFLHPKL--PATQKPMEGKASKLAKRVIACLDVRTNDK	
SEQ ID NO:02	GN VHAVQFHPE KSGGVGLSILRRFLNADSFNNKROKPMNGKASKLAKRVIACLDVRANDN	
SEQ ID NO:04	-----	
SEQ ID NO:08	-----	
SEQ ID NO:06	-----	
SEQ ID NO:10	-----	
SEQ ID NO:12	-----	
SEQ ID NO:14	-----	300
		241
SEQ ID NO:15	GDLVVTKGQYDVREQSNENEVRNLGKPVDLAQYKDGADSEISFLNITGFRDFPLGDL	
SEQ ID NO:02	GDLVVTKGQYDVRETEENEVRNLGKPVDELAQYLDGADSEVSFLNITGFRDFPLGDL	
SEQ ID NO:04	-----	
SEQ ID NO:08	-----	
SEQ ID NO:06	--LVVTKGDQYDVRDHTSSKEVRNLGKPVDLASQYIDGADSEVSFLNITGFRDFPLGDL	
SEQ ID NO:10	-----	
SEQ ID NO:12	-----	
SEQ ID NO:14	-----	360
		301

SEQ	ID	NO:15	MIQVLRQTSKNV	FVPLTVGGGIR	FTDASGRYYSS	LEVAAYFRSGA	DK	MSIG	S	DAVFAA	
SEQ	ID	NO:02	MLQVLQRASENV	FVPLTVGGGIR	FTDANGRYSS	LEVAAYFRSGA	DK	VSIG	S	DAVYTA	
SEQ	ID	NO:04	---	---	---	---	---	---	---	---	
SEQ	ID	NO:08	---	---	---	---	---	---	---	---	
SEQ	ID	NO:06	MLEVLRCASEKV	FVPLTVGGGIR	FTDANGRYSS	LEVAAYFRSGA	DK	ISIG	S	DAVYAA	
SEQ	ID	NO:10	---	---	---	---	---	---	---	---	
SEQ	ID	NO:12	---	---	---	---	---	---	---	---	
SEQ	ID	NO:14	---	---	---	---	---	---	---	---	
361											
SEQ	ID	NO:15	EEFIKSGVK	TKSSLEQ	ISR	VYGNQAVV	SI	D	PRR	VYVNH	PDDVPYK
SEQ	ID	NO:02	EEYIKTG	VKTGKSS	IEQ	ISTVYGNQAVV	SI	D	PRR	VYLRK	PDEVEFKA
SEQ	ID	NO:04	---	---	---	---	---	---	---	---	
SEQ	ID	NO:08	---	---	---	---	---	---	---	---	
SEQ	ID	NO:06	EAFLOTG	VKTGKSS	LEQ	ISR	VYGNQAVV	SI	D	PRR	VYVKSQEDVP
SEQ	ID	NO:10	---	---	---	---	---	---	---	---	
SEQ	ID	NO:12	---	---	---	---	---	---	---	---	
SEQ	ID	NO:14	---	---	---	---	---	---	---	---	
421											
SEQ	ID	NO:15	YAWYQCTV	SGGQGR	PIGAFELAKA	VEELGAG	E	ILLNC	INC	D	GQKGF
SEQ	ID	NO:02	YAWYQCTV	SGGQGR	PIGAYELAKA	VEELGAG	E	ILLNC	IDC	D	GQKGF
SEQ	ID	NO:04	---	---	---	---	---	---	---	---	
SEQ	ID	NO:08	---	---	---	---	---	---	---	---	
SEQ	ID	NO:06	YAWYQCTV	NGGRD	SRAIGA	YELAKA	VEELGAG	E	ILLNC	IDC	D
SEQ	ID	NO:10	---	---	---	---	---	---	---	---	
SEQ	ID	NO:12	---	---	---	---	---	---	---	---	
SEQ	ID	NO:14	YAWYQCTV	NGGREG	RPIGAYELAKA	VEELGAG	E	ILLNC	IDC	D	GQKGF
481											
SEQ	ID	NO:15	MIQVLRQTSKNV	FVPLTVGGGIR	FTDASGRYYSS	LEVAAYFRSGA	DK	MSIG	S	DAVFAA	
SEQ	ID	NO:02	MLQVLQRASENV	FVPLTVGGGIR	FTDANGRYSS	LEVAAYFRSGA	DK	VSIG	S	DAVYTA	
SEQ	ID	NO:04	---	---	---	---	---	---	---	---	
SEQ	ID	NO:08	---	---	---	---	---	---	---	---	
SEQ	ID	NO:06	MLEVLRCASEKV	FVPLTVGGGIR	FTDANGRYSS	LEVAAYFRSGA	DK	ISIG	S	DAVYAA	
SEQ	ID	NO:10	---	---	---	---	---	---	---	---	
SEQ	ID	NO:12	---	---	---	---	---	---	---	---	
SEQ	ID	NO:14	---	---	---	---	---	---	---	---	
420											
SEQ	ID	NO:15	EEFIKSGVK	TKSSLEQ	ISR	VYGNQAVV	SI	D	PRR	VYVNH	PDDVPYK
SEQ	ID	NO:02	EEYIKTG	VKTGKSS	IEQ	ISTVYGNQAVV	SI	D	PRR	VYLRK	PDEVEFKA
SEQ	ID	NO:04	---	---	---	---	---	---	---	---	
SEQ	ID	NO:08	---	---	---	---	---	---	---	---	
SEQ	ID	NO:06	EAFLOTG	VKTGKSS	LEQ	ISR	VYGNQAVV	SI	D	PRR	VYVKSQEDVP
SEQ	ID	NO:10	---	---	---	---	---	---	---	---	
SEQ	ID	NO:12	---	---	---	---	---	---	---	---	
SEQ	ID	NO:14	---	---	---	---	---	---	---	---	
480											
SEQ	ID	NO:15	YAWYQCTV	SGGQGR	PIGAFELAKA	VEELGAG	E	ILLNC	INC	D	GQKGF
SEQ	ID	NO:02	YAWYQCTV	SGGQGR	PIGAYELAKA	VEELGAG	E	ILLNC	IDC	D	GQKGF
SEQ	ID	NO:04	---	---	---	---	---	---	---	---	
SEQ	ID	NO:08	---	---	---	---	---	---	---	---	
SEQ	ID	NO:06	YAWYQCTV	NGGRD	SRAIGA	YELAKA	VEELGAG	E	ILLNC	IDC	D
SEQ	ID	NO:10	---	---	---	---	---	---	---	---	
SEQ	ID	NO:12	---	---	---	---	---	---	---	---	
SEQ	ID	NO:14	YAWYQCTV	NGGREG	RPIGAYELAKA	VEELGAG	E	ILLNC	IDC	D	GQKGF
540											

097831233

FIGURE 1

SEQ ID NO:15	GIPVIASSGAGTPDHFSEVFEEEDKRICRACCRHFFPPERGYQSQSVKEHLQEERIEVRI	
SEQ ID NO:02	NIPVIASSGAGVADHFSEVFNETNASAAAGIFHR-KEVPIKAVKEHLLKEGIEVRL	
SEQ ID NO:04	-----	
SEQ ID NO:08	-----	
SEQ ID NO:06	TIPVIASSGAGAVQHFSEIFEKTNASAAALAAGIFHR-KEVPILAVKEHLVNAGVEVRV	
SEQ ID NO:10	-----	
SEQ ID NO:12	-----	
SEQ ID NO:14	SIPVIASXGAGAPEHFSEVFYKTNASAAALAAGIFHR-KEVPIQSVKEHLLKEGIEVRI	598
		541

DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS

the specification of which is attached hereto unless the following box is checked:

☒ was filed on **04 NOVEMBER 1999** as U.S. Application No. _____ or PCT International Application No. **PCT/US99/25950** and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Application No.	Country	Filing Date	Priority Claimed (Yes/No)
-----------------	---------	-------------	---------------------------

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

U.S. Provisional Application No.

60/107,275

U.S. Filing Date

05 NOVEMBER 1998

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application No.	Filing Date	Status (patented, pending or abandoned)
-----------------	-------------	---

POWER OF ATTORNEY: I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Name: GREGORY J. FEULNER

Registration No. 41,744

Send correspondence and direct telephone calls to:

GREGORY J. FEULNER

E. I. du Pont de Nemours and Company
Legal - Patents
Wilmington, DE 19898, U.S.A.

Tel. No.
(302) 992-3749Fax No.
(302) 892-7949

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INVENTOR(S)

Full Name of Inventor 1	Last Name ALLEN	First Name STEPHEN	Middle Name M.
	Signature (please sign full name): <i>[Signature]</i>		Date: 12/16/99
Residence & Citizenship	City WILMINGTON	State or Foreign Country DELAWARE DE	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 2225 ROSEWOOD DRIVE	City WILMINGTON	State or Country DELAWARE Zip Code 19810
Full Name of Inventor 2	Last Name HUANG	First Name LISA	Middle Name L.
	Signature (please sign full name): <i>[Signature]</i>		Date: 12/20/99
Residence & Citizenship	City HOCKESSIN	State or Foreign Country DELAWARE DE	Country of Citizenship CN
Post Office Address	Post Office Address 1423 OLD WILMINGTON ROAD	City HOCKESSIN	State or Country DELAWARE Zip Code 19707
Full Name of Inventor 3	Last Name FALCO	First Name SAVERIO	Middle Name CARL
	Signature (please sign full name): <i>[Signature]</i>		Date: 12/22/99
Residence & Citizenship	City ARDEN	State or Foreign Country DELAWARE DE	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 1902 MILLERS ROAD	City ARDEN	State or Country DELAWARE Zip Code 19810

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99

DECLARATION AND POWER OF ATTORNEY - Page 2

Docket No.: **BB1129PCT**

Full Name of Inventor <i>fw</i>	Last Name RAFALSKI	First Name J.	Middle Name ANTONI
	Signature (please sign full name) <i>J. Antoni Rafalski</i>		Date <i>1-3-2000</i>
Residence & Citizenship	City WILMINGTON	State or Foreign Country DELAWARE <i>DE</i>	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 2028 LONGCOME DRIVE	City WILMINGTON	State or Country DELAWARE
			Zip Code 19810